What is it about?
Earlier studies have investigated whether variations in the CYP3A5 and CYP3A4 genes influence how individuals with epilepsy respond to the antiseizure medication Carbamazepine (CBZ). However, findings have been inconsistent. This review examines current research to determine if certain genetic differences in these genes affect CBZ’s effectiveness or how it is metabolized. We searched several research databases up until June 2023 to find studies that examined these genetic differences in the CYP3A4 and CYP3A5 genes and their impact on CBZ use in epilepsy patients. This review analyzed 23 studies with over 2,177 epilepsy patients. It found that certain genetic variations in CYP3A4 are associated with lower enzyme activity, affecting how CBZ is processed, while a variation in CYP3A5 affects CBZ levels in the bloodstream based on the dose.
Featured Image
Photo by julien Tromeur on Unsplash
Why is it important?
The CYP3A5 and CYP3A4 genes play an important role in carbamazepine (CBZ) metabolism. Specific genetic variations in these genes can impact how efficiently CBZ is processed in the body, leading to drug resistance and/or severe adverse drug reactions in patients with epilepsy.
Perspectives
Additional research involving diverse populations is needed to improve personalized treatment for epilepsy patients in clinical practice.
PhD Student Rachda Riffi
Ecole Supérieure en Sciences Biologiques d'Oran (ESSBO)
Read the Original
This page is a summary of: Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms, CNS & Neurological Disorders - Drug Targets, December 2024, Bentham Science Publishers,
DOI: 10.2174/0118715273298953240529100325.
You can read the full text:
Contributors
The following have contributed to this page
